1:49 PM
 | 
Oct 15, 2018
 |  BC Extra  |  Clinical News

Krystal gains on early data for topical gene therapy in skin blistering disease

Krystal Biotech Inc. (NASDAQ:KRYS) added $4.32 (28%) to $20 on Monday when it reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints in two adults with recessive dystrophic epidermolysis bullosa.

KB103 is a replication-defective, non-integrating HSV-1 viral vector engineered using the company's STAR-D platform to deliver functional human collagen type VII (COL7A1) genes directly to the patients'...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >